跳至主要内容
临床试验/IRCT20130418013058N17
IRCT20130418013058N17
尚未招募
2 期

Investigating the effect of crocin on the severity of fatigue, pain and quality of life in patients with multiple sclerosis

Mashhad University of Medical Sciences0 个研究点目标入组 40 人待定

概览

阶段
2 期
干预措施
未指定
疾病 / 适应症
未指定
发起方
Mashhad University of Medical Sciences
入组人数
40
状态
尚未招募
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
2年前
研究类型
Interventional
性别
All

研究者

入排标准

入选标准

  • Definitive diagnosis of MS with neurologist visit, based on the McDonald diagnostic criteria, at least 6 months have passed since the diagnosis.
  • Patients with relapsing\-remitting MS or RRMS receiving first\- and second\-line MS disease therapy.
  • No relapse attacks one month before of the study.
  • Expression of willingness to participate in the study.
  • 0 to 5 points based on expanded disability status scale.
  • ?a fatigue intensity score equal to or higher than 4 according to the Fatigue severity scale
  • Having a feeling of chronic pain in at least one of the body organs and a score higher than 4 based on Numerical rating scale.
  • MS patients who take first and second line drugs (dimethyl fumarate, Resigen, Betaferon, Triflunomide, Fingolimido Cinomer).

排除标准

  • Suffering from other diseases such as (chronic diseases, heart failure, glands, breathing, liver, kidney, skeletal\-muscular) and mental diseases and severe depression.
  • Addiction to alcohol, drugs and psychedelics
  • History of allergy to saffron
  • Pregnancy and breastfeeding
  • The presence of severe infection and inflammation, varicose veins, active thrombosis, damage to organs such as fractures.
  • Motor disability score higher than 6
  • Getting any other serious diseases such as heart, liver and kidney diseases during treatment
  • Do heavy exercise daily
  • Any use of anti\-inflammatory and antioxidant drugs as a supplement or Amantadine as an anti\-fatigue drug
  • Unwillingness to participate in the study or continue the treatment process

结局指标

主要结局

未指定

相似试验